Management of Dyslipidemia in the Metabolic Syndrome: Recommendations of the Spanish HDL-Forum

ISSN： 1175-3277

Source： American Journal of Cardiovascular Drugs, Vol.7, Iss.1, 2007-01, pp. : 39-58

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Dyslipidemia in the metabolic syndrome

By Chan Dick Watts Gerald

The Journal of Drug Evaluation, Vol. 2, Iss. 1, 2004-01 ,pp. : 3-34

Taylor & Francis Ltd

Access to resources Recommend Favorite

Pharmacotherapy of Mixed Dyslipidemia in the Metabolic Syndrome

Current Clinical Pharmacology, Vol. 5, Iss. 2, 2010-05 ,pp. : 133-139

Bentham Science Publishers

Access to resources Recommend Favorite

Drug Combinations for Dyslipidemia and Obesity Treatment in Metabolic Syndrome

Current Pharmaceutical Design, Vol. 15, Iss. 29, 2009-10 ,pp. : 3446-3462

Bentham Science Publishers

Access to resources Recommend Favorite

Progranulin, a New Adipokine at the Crossroads of Metabolic Syndrome, Diabetes, Dyslipidemia and Hypertension

Current Pharmaceutical Design, Vol. 23, Iss. 10, 2017-05 ,pp. : 1533-1539

Bentham Science Publishers

Access to resources Recommend Favorite

Significance of High Density Lipoprotein-Cholesterol in Cardiovascular Risk Prevention: Recommendations of the HDL Forum1 1 Affiliation details for individual members of the HDL Forum are available in the Acknowledgments section.

By Juan F. Ascaso

American Journal of Cardiovascular Drugs, Vol. 4, Iss. 5, 2004-01 ,pp. : 299-314

Adis International

Access to resources Recommend Favorite